New incident report
Incident Report Number: 2021-2672
Registrant Reference Number: 2020-CA-000348
Registrant Name (Full Legal Name no abbreviations): The Hartz Mountain Corporation
Address: 400 Plaza Drive
City: Secaucus
Prov / State: New Jersey
Country: USA
Postal Code: 07094-3688
Domestic Animal
Country: CANADA
Prov / State: NOVA SCOTIA
PMRA Registration No. 25655 PMRA Submission No. EPA Registration No.
Product Name: Hartz UltraGuard Cat Flea and Tick Spray Spray
Yes
Unknown
Site: Animal / Usage sur un animal domestique
Animal's Owner
Cat / Chat
Domestic (Unspecified)
1
Male
0.30
2.27
kg
Skin
Unknown / Inconnu
<=30 min / <=30 min
System
Unknown / Inconnu
No
No
Unknown/Inconnu
Treatment / Traitement
(eg. description of the frequency and severity of the symptoms
On 01-Oct-2020, a 0.30 year old, approximately 2.27 kilogram, intact, male, Domestic (Unspecified) cat, in unknown condition, with no known concomitant medical conditions, was administered 1 spray of Hartz UltraGuard Cat Flea and Tick Spray (Tetrachlorvinphos) via the topical route by the animal owner. Approximately 30 minutes later, the cat was found hiding in the closet and was exhibiting foaming at the mouth and his body was limp. The animal owner then rinsed the cat with water and wiped its mouth and the symptoms continued. Recommended oral dilution of food and water, during consultation. The cat willingly ate his food and drank water and his symptoms significantly improved but continued. Recommended continuing to monitor the cat at home and seek veterinary evaluation if the symptoms persisted and/or if any new symptoms developed. No further information was received in this case.
Minor
The information contained in this report is based on self-reported statements provided to the registrant during telephone interview(s). These self-reported descriptions of an incident have not been independently verified to be factually correct or complete descriptions of the incident. For that reason, information contained in this report does not and cannot form the basis for a determination of whether the reported clinical effects are causally related to exposure to the product identified in the telephone interviews.